Pruritus treatment
Pro Research Analysisby 
Searched over 200M research papers for "pruritus treatment"
Effective Treatments for Pruritus: A Comprehensive Overview
Pruritus, commonly known as itching, is a distressing symptom associated with various dermatological and systemic conditions. Effective management of pruritus is crucial for improving patients' quality of life. This article synthesizes recent research on the treatment of pruritus, highlighting both established and emerging therapies.
Topical Treatments for Pruritus
Topical Opioid Receptor Antagonists
Topically applied naltrexone, an opioid receptor antagonist, has shown promise in treating severe pruritus. In a study involving patients with various chronic pruritic disorders, more than 70% experienced significant itch reduction with a 1% naltrexone cream. The treatment also increased epidermal mu-opiate receptor (MOR) expression, correlating with clinical improvement. A placebo-controlled trial further confirmed naltrexone's efficacy, demonstrating a 29.4% better effect compared to placebo .
Gamma-Linolenic Acid (GLA)
GLA, known for its immune-modulating properties, has been effective in treating refractory uremic pruritus. In a randomized, double-blind, placebo-controlled study, GLA cream significantly alleviated pruritus in dialysis patients, outperforming placebo-based creams .
TrkA Kinase Inhibitors
CT327, a TrkA kinase inhibitor, has shown efficacy in reducing pruritus in psoriasis patients. A Phase 2b clinical trial reported significant reductions in pruritus and modified Psoriasis Area and Severity Index scores in patients with moderate to severe pruritus at baseline .
Systemic Treatments for Pruritus
Serlopitant
Serlopitant, a neurokinin 1 receptor (NK1R) antagonist, has been evaluated for chronic pruritus of unknown origin (CPUO). A study involving different doses of serlopitant found that the 5 mg dose may significantly reduce pruritus intensity compared to placebo. However, the evidence is of low certainty, and further research is needed to confirm these findings .
Systemic Treatments for Atopic Dermatitis
A meta-analysis of systemic treatments for atopic dermatitis (AD) revealed that various therapies, including cyclosporine, phototherapy, and biologics like dupilumab, effectively reduce pruritus. Upadacitinib and nemolizumab showed the highest efficacy in pruritus reduction .
Systemic Treatments for Psoriasis
Systemic treatments for psoriasis, such as anti-IL-17, JAK inhibitors, adalimumab, and apremilast, have been effective in reducing pruritus. A meta-analysis confirmed that these treatments significantly alleviate pruritus, although the effect size varies among different therapies .
Gabapentin for Uremic Pruritus
Gabapentin has the most substantial evidence supporting its efficacy in treating uremic pruritus. A systematic review of randomized controlled trials highlighted gabapentin's effectiveness, although evidence for other treatments remains limited .
Emerging Therapies Targeting the Neural System
Recent advancements in understanding the neural pathways involved in pruritus have led to the development of novel systemic therapies. These include NK-1 inhibitors, opioid receptor modulators, and drugs targeting specific itch receptors such as Mrgpr, Nav1.7, and PAR2. These emerging therapies show promise in treating chronic pruritus with potentially fewer side effects .
Conclusion
The management of pruritus involves a combination of topical and systemic treatments, with emerging therapies offering new hope for patients. Topical naltrexone, GLA, and CT327 have shown significant efficacy in reducing pruritus. Systemic treatments like serlopitant, biologics for AD, and gabapentin for uremic pruritus provide substantial relief. Continued research and clinical trials are essential to validate these findings and develop standardized treatment protocols for pruritus.
Sources and full results
Most relevant research papers on this topic